Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2018 Sep 1.

Published in final edited form as: Circ Cardiovasc Interv. 2017 Sep;10(9):e005487. doi: 10.1161/CIRCINTERVENTIONS.117.005487

Table 1.

Clinical, laboratory, and demographic data of EH and ARAS patients.

	Elamipretide (N=6)	Placebo (N=8)	P value
Gender (%Men)^*	3 (50%)	4 (50%)	0.99
Age (years)	66.7 ± 6.8	72.5 ± 8.1	0.17
Creatinine (mg/dl)	1.58 ± 0.36	1.83 ± 0.52	0.32
Iothalamate clearance (mL/min)	46.8 ± 24.5	43.6 ± 12.3	0.99
Statins (yes/no) (%)^*	5/1 (83%)	5/3 (63%)	0.58
Number of anti-HTN drugs^#	3.5 (2, 5)	4 (2, 6)	0.44
SBP(mmHg)	154.2 ±16.3	155.2 ± 19.5	0.92
DBP (mmHg)	79.2 ± 9.1	72.5 ± 15.4	0.33
Weight (kg)	90.7 ± 35.3	83.8 ± 14.6	0.66
BMI (kg/m²)	33 ± 12.5	29.4 ± 3.9	0.51
Hematocrit %	37.3 ± 2.6	36.2 ± 2.5	0.42

Mean±SD, GFR=glomerular filtration rate, Anti-HTN=antihypertensive, SBP=systolic blood pressure, DBP=diastolic blood pressure, ARAS= atherosclerotic Renal artery stenosis, N= number of patients.

^#

Median (range) reported due to skewed data, P value obtained from Wilcoxon rank sum test,

^*

Fisher’s exact test.